Is afamelanotide FDA-approved, and what does the research show?

What is afamelanotide?

Afamelanotide is a prescription medicine for adults with erythropoietic protoporphyria, or EPP, a rare inherited disorder in which light on the skin causes severe pain ⁶, ¹. It is not a wellness, weight-loss or performance peptide. Its label carries one indication, for EPP, and names no cosmetic use ¹.

The drug is a synthetic peptide, a short chain of 13 amino acids, the building blocks of proteins ¹. The label calls it "a structural analog of α-melanocyte stimulating hormone (α-MSH)," meaning a close copy of a hormone the body makes ¹. The European regulator describes that hormone as one "which stimulates the production of a brown-black pigment in the skin" ². Afamelanotide is sold as Scenesse, a small solid rod that the body absorbs, placed under the skin as an implant ¹. The label says it "should be administered by a health care professional" trained in the procedure ¹.

FDA describes EPP as "a rare disorder caused by mutations leading to impaired activity of ferrochelatase, an enzyme involved in heme production" ⁵. Heme is part of hemoglobin, the molecule that carries oxygen in red blood cells ⁵. With the enzyme impaired, a substance called protoporphyrin IX, or PPIX, builds up in the body ⁵. FDA's announcement continues: "Light reaching the skin can react with PPIX causing intense skin pain and skin changes, such as redness and thickening" ⁵.

The trial investigators wrote that the pain starts 1 to 20 minutes after direct sun exposure and can last for several days ⁶. It "does not respond to pain medications, including narcotic analgesics" ⁶. A guideline published in 2022 cites an older estimate of 1 case in 109,000 people in Europe ⁷. It adds that genetic databases point to about 1 in 17,000 among Caucasians ⁷.

Is afamelanotide FDA-approved?

Yes, for one use. FDA approved Scenesse (afamelanotide) on October 8, 2019, under application NDA 210797 ³, ⁵. Its marketing status is "Prescription" as of November 9, 2026, the date of the Drugs@FDA record's data ³.

The label says Scenesse "is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)" ¹. A phototoxic reaction is harm that light does to the skin; FDA's announcement glosses the phrase as "damage to skin" ⁵. The indication reads the same in the label approved in 2019 ⁸. FDA said that before this approval "there were no FDA-approved treatments to help erythropoietic protoporphyria patients increase their light exposure" ⁵.

FDA gave the application Priority Review, under which FDA aims to act within 6 months rather than the standard 10 ⁵, ⁹. Scenesse also held Orphan Drug designation, "which provides incentives to assist and encourage the development of drugs for rare diseases" ⁵. The approval did not replace sun protection. The label's instruction reads: "Maintain sun and light protection measures during treatment with SCENESSE to prevent phototoxic reactions related to EPP" ¹.

Europe acted first. The European Commission granted a marketing authorization for Scenesse on December 22, 2014, with the indication "Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)" ². The European Medicines Agency says the drug was authorized under "exceptional circumstances" ². Its stated reason: "it has not been possible to obtain complete information about the benefits of Scenesse, in part due to the rarity of the disease" ².

The label treats darker skin as an effect to be watched: Scenesse "may lead to generalized increased skin pigmentation and darkening of pre-existing nevi and ephelides because of its pharmacologic effect" ¹. Nevi are moles, and ephelides are freckles.

See the FDA status of every peptide, updated weekly.

How does afamelanotide work?

The account is the label's and the European regulator's, for an approved drug ², ¹. Afamelanotide "is a melanocortin receptor agonist and binds predominantly to MC1-R," the melanocortin 1 receptor ¹. An agonist switches a receptor on. The trial investigators place this receptor on skin cells that include melanocytes, the cells that make pigment ⁶. The label says the drug "increases production of eumelanin in the skin independently of exposure to sunlight or artificial UV light sources" ¹.

Eumelanin is a brown-black skin pigment, which in the European regulator's words "is produced during exposure to sunlight to block the penetration of light into cells" ². In EPP, the agency explains, more eumelanin "reduces the penetration of light through the skin, thus helping to prevent the painful reactions" ². The trial investigators reported that protoporphyrin levels "do not change with afamelanotide treatment" ⁶.

In 12 healthy adults given a single implant, 9 had their last measurable blood level of the drug at 96 hours ¹. The label puts the apparent half-life, the time for the blood level to fall by half, at about 15 hours ¹. It adds that the drug's "metabolic profile has not been fully characterized" ¹.

What does the research show?

The evidence level is Approved for a use, for adults with EPP only ¹. The label describes three trials in which subjects were assigned at random to Scenesse or to a vehicle, an implant without the drug ⁶, ¹. The published trial report calls the vehicle a placebo ⁶. Two of them "were designed to assess exposure to direct sunlight on days with no phototoxic pain" ¹. Their subjects were 98 percent Caucasian, with a mean age of 40 ¹.

Study CUV039 enrolled 93 subjects, of whom 48 received Scenesse and 45 the vehicle ¹. Each received three implants, one every 2 months, and was followed for 180 days ¹. Subjects recorded their hours in direct sunlight between 10 am and 6 pm and whether they had pain that day ¹. The median total of hours in direct sunlight on days with no pain was 64.1 with Scenesse and 40.5 with the vehicle ¹. A median is the middle subject's figure.

Study CUV029 enrolled 74 subjects, 38 on Scenesse and 36 on the vehicle, who received five implants and were followed for 270 days ¹. Its measure was narrower: hours outdoors between 10 am and 3 pm on pain-free days when "most of the day" was spent in direct sunlight ¹. Days of mixed sun and shade were left out ¹. The median total was 6.0 hours with Scenesse and 0.75 hours with the vehicle ¹.

A paper published in July 2015 reports two phase 3 trials, the late-stage tests a company runs before it seeks approval ⁶. Its U.S. trial carries the registry number the label prints for CUV039 ⁶, ¹. Its European trial carries the registry number the label prints for CUV029 ⁶, ¹. Both were double-blind: neither patients nor staff were told who had the drug ⁶.

The paper counts 94 patients in the U.S. trial and gives medians of 69.4 hours with afamelanotide and 40.8 with placebo ⁶. It reports P = 0.04 for that gap, meaning chance alone would produce one that large about 4 times in 100 ⁶. For the European trial it gives 6.0 against 0.8 hours, with P = 0.005 ⁶. The paper's 94 includes one placebo patient excluded before the first implant, which leaves the label's 93 ⁶, ¹.

Painful episodes told a mixed story. In the European trial the afamelanotide group had 77 phototoxic reactions and the placebo group 146 (P = 0.04) ⁶. In the U.S. trial the counts were 46 and 43, with no significant difference (P = 0.60) ⁶.

A general skin questionnaire, the Dermatology Life Quality Index, "did not change over time in either study-drug group" ⁶. On a questionnaire written for EPP, the U.S. trial's mean change at day 180 was 51.1 with afamelanotide against 36.8 with placebo (P = 0.02) ⁶. In the European trial the day-270 scores were 79.7 against 67.2 (P = 0.06, not significant at the usual 0.05 level) ⁶.

The authors named limits. Darker skin showed who had the drug, so the pigmentation "partially unblinded the trial" ⁶. Patients who did go into the sun did so in a limited way, they wrote, which "probably decreased the magnitude of the treatment benefit" ⁶. Clinuvel Pharmaceuticals, the maker, designed and sponsored both trials ⁶.

Europe's medicines committee noted that "the additional time spent in sunlight was small" ². It weighed quality of life, unmet need and the mild side effects seen in short-term treatment in recommending approval ².

Studied in people in routine care: a single-center cohort study, published online in March 2020, followed 117 patients with EPP treated in Rotterdam ⁴. A cohort study follows a group of treated patients over time, here with no untreated group beside them ⁴. Data were collected between June 2016 and September 2018, with a median follow-up of 2.0 years, and 115 of the 117 (98 percent) continued treatment ⁴.

Compared with their own baseline, patients' mean time outside rose by 6.1 hours a week ⁴. The 95 percent confidence interval, the range the true figure probably lies in, was 3.62 to 8.67 hours ⁴. Phototoxic reactions were less painful, "but there was no significant difference in number or duration of reactions" ⁴. Three of its authors reported financial support, grants or travel fees from Clinuvel ⁴.

A consensus guideline from the Porphyrias Consortium, a research network of specialists, was published online in August 2022 ⁷. It states that "afamelanotide is recommended for the prevention of phototoxic symptoms in EPP" ⁷. The guideline grades this Class I, level B: "benefit >>> risk, limited published data" ⁷. It adds that "access is limited in the US due to the high cost and restricted sites for administration" ⁷.

Much has not been studied. The label says safety and effectiveness "have not been established in pediatric patients," and that no drug interaction studies were conducted ¹. Neither the label nor the text of the phase 3 paper reports any result for body weight, muscle, aging or athletic performance ⁶, ¹.

What are the side effects?

The label's figures come from three randomized trials in 244 adults with EPP "without significant liver involvement," 125 on Scenesse and 119 on the vehicle ¹. Through month 6, implant site reactions occurred in 21 percent of the Scenesse group and 10 percent of the vehicle group ¹. Nausea occurred in 19 percent against 14 percent, throat pain in 7 against 5, cough in 6 against 3, and fatigue in 6 against 3 ¹.

Skin darkening (hyperpigmentation) was recorded in 4 percent against none ¹. A mole (melanocytic nevus) was recorded as an adverse reaction in 4 percent against 2 percent ¹. The most common implant site reaction with Scenesse was discoloration, in 10 percent ¹.

In the phase 3 paper there were no deaths, and four serious adverse events occurred in the afamelanotide groups ⁶. The placebo groups had two, a pulmonary embolus (a blood clot in the lung) and a melanoma ⁶. All six were "considered by the principal investigator to be unrelated to the study drug" ⁶. The authors reported "mild hyperpigmentation at the implant site in one third of the patients who received afamelanotide and moles that darkened in a few patients who received this drug" ⁶. The Rotterdam cohort's report reads: "Minor self-limiting adverse events occurred, such as nausea, fatigue, and headache" ⁴.

The warnings changed after approval. The 2019 label listed no contraindications: the section read "None" ⁸. The label as revised in August 2024 says Scenesse is "contraindicated in patients with a history of severe hypersensitivity reaction to afamelanotide or to any of the excipients in SCENESSE" ¹, ³. Hypersensitivity is an allergic reaction, and excipients are the implant's inactive ingredients.

The warning reads: "Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of SCENESSE" ¹. Anaphylaxis is a severe, whole-body allergic reaction. The reports since approval also include urticaria (hives) and angioedema, a deeper swelling ¹. After a serious reaction, the label says, "The patient should not receive any further treatment with SCENESSE" ¹. Its procedure has the patient monitored for 30 minutes after the implant is placed ¹.

The second warning is skin monitoring. The label says: "A full body skin examination (twice yearly) is recommended to monitor pre-existing and new skin pigmentary lesions" ¹. On cancer risk it states: "Carcinogenicity studies have not been conducted with SCENESSE" ¹.

On pregnancy the label says, "There are no data on SCENESSE use in pregnant women," and it has none on breast milk ¹. The 2022 guideline concludes that the drug "cannot be recommended for pregnant women" ⁷. Of the 125 subjects treated, 4 were 65 or older, too few to show whether older patients respond differently ¹. The U.S. label calls the effect of kidney or liver impairment on the drug's blood levels "unknown" ¹. The European regulator goes further: "Scenesse must not be used in patients with reduced liver or kidney function" ².

In sport

Afamelanotide is not named on WADA's 2026 Prohibited List ¹⁰. WADA, the World Anti-Doping Agency, groups peptide hormones, growth factors and related substances in section S2 ¹⁰. Neither afamelanotide nor Scenesse appears there or in any other section, and the list names no melanocortin or melanocyte-stimulating hormone ¹⁰.

What JumpstartMD offers

JumpstartMD does not prescribe afamelanotide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.